Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Alterity Therapeutics ( (AU:ATH) ) has provided an update.
Alterity Therapeutics announced the results of its 2025 Annual General Meeting, highlighting the approval of resolutions by shareholders. The company continues to make strides in its clinical trials, particularly with ATH434, which has shown positive results in treating Multiple System Atrophy, potentially enhancing its market position and impact on stakeholders.
More about Alterity Therapeutics
Alterity Therapeutics is a clinical stage biotechnology company focused on developing therapies for neurodegenerative diseases, particularly Parkinson’s disease and related disorders. The company has shown efficacy in its lead asset, ATH434, through clinical trials for Multiple System Atrophy, and is engaged in drug discovery for neurological diseases.
Average Trading Volume: 14,942,225
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$97.88M
For an in-depth examination of ATH stock, go to TipRanks’ Overview page.